Relationship between Prostaglandin Receptor EP4 and Renal Diseases

doi:10.3969/j.issn.2095-1396.2020.03.010

Abstract

Abstract:

Prostaglandin receptor 4 （EP4） is the receptor of endogenous lipid medium prostaglandin E2 （PGE2），belongs to the G protein coupled receptor （GPCR） . EP4 is widely distributed in almost all tissues and organs in the body. In the kidney，there is high expression in the glomerular granulosa cells and epithelial cells，distal convoluted tubules and cortical collecting tubular cells. Because EP4 can be coupled with the Gs，Gi protein pathways at the same time，it is closely related to the physiological functions and pathophysiological processes，such as vascular tone，oxidative stress，inflammation，cell proliferation. Studies on systemic and renal specific EP4 knockout mice and the development of selective EP4 agonist/antagonist proved EP4 receptors play a key role in the kidney，the PGE2-EP4 signaling pathway can produce protective and adverse effects at the same time. This review article analyzes and summarizes the association of EP4 receptor in renal diseases，including renal hypertension，renal ischemia/reperfusion injury，nephrogenic diabetes insipidus，glomerulonephritis，glomerulosclerosis，chronic kidney disease and autosomal dominant polycystic kidney disease.

Key words: prostaglandin receptor 4, Gs, Gi, EP4 agonist/antagonist, kidney related diseases

CLC Number:

R363

Cite this article

XIONG Meng-yao, JIA Ying-li, YANG Bao-xue. Relationship between Prostaglandin Receptor EP4 and Renal Diseases[J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 54-64.

share this article

0
/ Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: http://actanp.hebeinu.edu.cn/EN/10.3969/j.issn.2095-1396.2020.03.010

http://actanp.hebeinu.edu.cn/EN/Y2020/V10/I3/54

References

1. Wang J, M, Liu, X, Zhang, et al. Physiological and pathophysiological implications of PGE and the PGE synthases in the kidney [J].Prostaglandins & other lipid mediators,2018,134:1-6.

2. James V Michael, Adelina Gavrila, Ajay P Nayak, et al. Cooperativity of E-prostanoid receptor subtypes in regulating signaling and growth inhibition in human airway smooth muscle [J].FASEB J: Official Publication of the Federation of American Societies for Experimental Biology, 2019, 33(4): 4780-4789.

3. Yukihiko Sugimoto, Shuh Narumiya. Prostaglandin E receptors [J]. J Biol Chem, 2007, 282(16): 11613-11617.

4. Jean B Regard, Isaac T Sato, Shaun R Coughlin. Anatomical profiling of G protein-coupled receptor expression [J].Cell, 2008, 135(3): 561-71.

5. Arantzazu Alfranca, Miguel A Iniguez, Manuel Fresno, et al. Prostanoid signal transduction and gene expression in the endothelium: role in cardiovascular diseases [J].Cardiovasc Res, 2006, 70(3): 446-56.

6. Utako Yokoyama, Kousaku Iwatsubo, Masanarl Umemura, et al. The prostanoid EP4 receptor and its signaling pathway [J].Pharmacological Reviews, 2013, 65(3): 1010-52.

7. Brian K Kobilka. G protein coupled receptor structure and activation [J].Biochim Biophys Acta, 2007, 1768(4): 794-807.

8. Shinsuke Mizoguchi, Amanda S Wolf-Johnson, Jian-shu Ni, et al. The role of prostaglandin and E series prostaglandin receptor type 4 receptors in the development of bladder overactivity in a rat model of chemically induced prostatic inflammation [J].BJU International, 2019, 124(5): 883-891.

9. Chandramohan Natarajan, Aaron N Hata, Heldi E Hamm, et al. Extracellular loop II modulates GTP sensitivity of the prostaglandin EP3 receptor [J].Molecular Pharmacology, 2013, 83(1): 206-216.

10. Yosuke Toyoda, Kazushi Morimoto, Ryoji Suno, et al. Ligand binding to human prostaglandin E receptor EP at the lipid-bilayer interface [J].Nature Chemical Biology, 2019, 15(1): 18-26.

11. Lamine Aoudjit, Anna Potapov, Tomoko Takano. Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor [J].Am J Physiol Renal Physiol, 2006, 290(6): F1534-42.

12. Emi Yamamoto, Takeshi Izawa, Mitsuru Kuwamura, et al. Immunohistochemical expressions of main PGE(2) biosynthesis-related enzymes and PGE(2) receptor in rat nephrogenesis [J].J Toxicologic Pathology, 2011, 24(4): 257-61.

13. Boye L Jensen, Jane Stubbe, Pernille Hansen, et al. Localization of prostaglandin E(2) EP2 and EP4 receptors in the rat kidney [J].American J Physiology Renal Physiology, 2001, 280(6): F1001-F1009.

14. Morath R, Thomas Klein, H W Seyberth, et al. Immunolocalization of the four prostaglandin E2 receptor proteins EP1, EP2, EP3, and EP4 in human kidney [J].J the American Society of Nephrology : JASN, 1999, 10(9): 1851-60.

15. Tessa A Castleberry, Bi-hong Lu, Steven L Smock, et al. Molecular cloning and functional characterization of the canine prostaglandin E2 receptor EP4 subtype [J].Prostaglandins & Other Lipid Mediators, 2001, 65(4): 167-187.

16. Ren Yi-lin, Martin A D'Ambrosio, Jeffrey L Garvin, et al. Prostaglandin E2 mediates connecting tubule glomerular feedback [J].Hypertension (Dallas, Tex: 1979), 2013, 62(6): 1123-1128.

17. Nitta M, Ichiro Hirata, K Toshina, et al. Expression of the EP4 prostaglandin E2 receptor subtype with rat dextran sodium sulphate colitis: colitis suppression by a selective agonist, ONO-AE1-329 [J].Scandinavian J Immunology, 2002, 56(1): 66-75.

18. Chabha Benyahia, Ingrid Gomez, L Kanyinda, et al. PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy? [J].Pulmonary Pharmacology & Therapeutics, 2012, 25(1): 115-118.

19. Nabll Foudi, Kotelevets L, Louedec L, et al. Vasorelaxation induced by prostaglandin E2 in human pulmonary vein: role of the EP4 receptor subtype [J].Br J Pharmacol, 2008, 154(8): 1631-1639.

20. Konya V, Üllen A, Kampitsch N, et al. Endothelial E-type prostanoid 4 receptors promote barrier function and inhibit neutrophil trafficking [J]. The J Allergy and Clinical Immunology, 2013, 131(2): 532-40.e1-2.

21. Petra Luschnig-Schratl, Eva M Sturm, Viktoria Konya, et al. EP4 receptor stimulation down-regulates human eosinophil function [J].Cellular and MolecularLife Sciences : CMLS, 2011, 68(21): 3573-3587.

22. Sonia Philipose, Viktoria Konya, Ivana Sreckovic, et al. The prostaglandin E2 receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation [J].Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30(12): 2416-2423.

23. Vukicevic S, Simic P, Borovecki F, et al. Role of EP2 and EP4 receptor-selective agonists of prostaglandin E(2) in acute and chronic kidney failure [J].Kidney International, 2006, 70(6): 1099-1106.

24. Liu Yu, Madhumitha Rajagopal, Kim Lee, et al. Prostaglandin E(2) mediates proliferation and chloride secretion in ADPKD cystic renal epithelia [J].American J Physiology Renal Physiology, 2012, 303(10): F1425- F1434.

25. Martin Leduc, Billy Breton, Celine Galés, et al. Functional selectivity of natural and synthetic prostaglandin EP4 receptor ligands [J].The J Pharmacology and Experimental Therapeutics, 2009, 331(1): 297-307.

26. Hiromichi Fujino, John W Regan. EP(4) prostanoid receptor coupling to a pertussis toxin-sensitive inhibitory G protein [J].Molecular Pharmacology, 2006, 69(1): 5.

27. Madhu B Anand-Srivastava. Modulation of Gi proteins in hypertension: role of angiotensin II and oxidative stress [J].Curr Cardiol Rev, 2010, 6(4): 298-308.

28. Hiromichi Fujino, Kimberly A West, John W Regan Phosphorylation of glycogen synthase kinase-3 and stimulation of T-cell factor signaling following activation of EP2 and EP4 prostanoid receptors by prostaglandin E2 [J].The J Biological Chemistry, 2002, 277(4): 2614-2619.

29. Fujino Hiromichi, Xu Wei, John W Regan. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases [J].The J Biological Chemistry, 2003, 278(14): 12151-12156.

30. Peng Xiao-jie, Li Jian-zhong, Tan si-wei, et al. COX-1/PGE/EP4 alleviates mucosal injury by upregulating β-arr1-mediated Akt signaling in colitis [J].Scientific Reports, 2017, 7(1): 1055.

31. Jonathan Constance, Alfred Balch, Chris Stockmann, et al. A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates [J].Archives of Disease in Childhood. Fetal and Neonatal Edition, 2016, 101(3): F236-43.

32. Constance J E, D Reith, R M Ward, et al. Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin [J]. J Perinatology : Official J the California Perinatal Association, 2017, 37(10): 1093-1102.

33. Stefanie Frölich, Anke Olliges, Nikias Kern, et al. Temporal expression of the PGE2 synthetic system in the kidney is associated with the time frame of renal developmental vulnerability to cyclooxygenase-2 inhibition [J].American J Physiology. Renal Physiology, 2012, 303(2): F209-19.

34. Lamine Aoudjit, Anna Potapov, Tomoko Takano. Prostaglandin E2 promotes cell survival of glomerular epithelial cells via the EP4 receptor [J].American J Physiology Renal physiology, 2006, 290(6): F1534- F1542.

35. Maria Augusta Gaspar. Renovascular hypertension: The current approach [J].Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology, 2019, 38(12): 869-871.

36. Silva B R, L Pernomian, Tiago Dai-Cin De Paula, et al. Endothelial nitric oxide synthase and cyclooxygenase are activated by hydrogen peroxide in renal hypertensive rat aorta [J].European J Pharmacology, 2017, 814: 87-94.

37. Carie S Facemire, Robert Griffiths, Laurent P Audoly, et al. The impact of microsomal prostaglandin e synthase 1 on blood pressure is determined by genetic background [J].Hypertension (Dallas, Tex: 1979), 2010, 55(2): 531-538.

38. Zhang Dong-juan, Chen Li-hong, Zhang Ya-hua, et al. Enhanced pressor response to acute Ang II infusion in mice lacking membrane-associated prostaglandin E2 synthase-1 [J].Acta Pharmacologica Sinica, 2010, 31(10): 1284-1292.

39. Chen Li-hong, Miao Yi-fei, Zhang Ya-hua, et al. Inactivation of the E-prostanoid 3 receptor attenuates the angiotensin II pressor response via decreasing arterial contractility [J].Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32(12): 3024-3032.

40. Liu Bin, Wu Xiang-zhong, Zeng Ru-hui, et al. Prostaglandin E sequentially activates E-prostanoid receptor-3 and thromboxane prostanoid receptor to evoke contraction and increase in resistance of the mouse renal vasculature [J].FASEB J : official publication of the Federation of American Societies for Experimental Biology, 2020, 34(2): 2568-2578.

41. Laurent P Audoly, Stephen L Tilley, Jennifer Goulet, et al. Identification of specific EP receptors responsible for the hemodynamic effects of PGE2 [J].The American J Physiology, 1999, 277(3): H924-30.

42. Hao C M, Breyer M D. Physiologic and pathophysiologic roles of lipid mediators in the kidney [J].Kidney International, 2007, 71(11): 1105-1115.

43. Frank Schweda, Jurgen Klar, Shuh Narumiya, et al. Stimulation of renin release by prostaglandin E2 is mediated by EP2 and EP4 receptors in mouse kidneys [J].American J Physiology. Renal Physiology, 2004, 287(3): F427-F433.

44. Ulla G Friis, Jane Stubbe, Torhen R Uhrenholt, et al. Prostaglandin E2 EP2 and EP4 receptor activation mediates cAMP-dependent hyperpolarization and exocytosis of renin in juxtaglomerular cells [J].Am J Physiol Renal Physiol, 2005, 289(5): F989-97.

45. Shigeo Negi, Daisuke Koreeda, Sou Kobayashi, et al. Acute kidney injury: Epidemiology, outcomes, complications, and therapeutic strategies [J].Seminars in Dialysis, 2018, 31(5): 519-527.

46. Stephanie F Smith, Sarah A Hosgood, Michael L Nicholson. Ischemia-reperfusion injury in renal transplantation: 3 key signaling pathways in tubular epithelial cells [J].Kidney International, 2019, 95(1): 50-56.

47. Maryam Malek, Mehdi Nematbakhsh. Renal ischemia/reperfusion injury; from pathophysiology to treatment [J].J Renal Injury Prevention, 2015, 4(2): 20-27.

48. Nur Arfian, Santosa Budiharjo, Dian Prasetyo Wibisono, et al. Vitamin D ameliorates kidney ischemia reperfusion injury via reduction of inflammation and myofibroblast expansion [J].The Kobe J Medical Sciences, 2020, 65(4): E138-E143.

49. Li Feng, Edward Suarez Moreira Bahnson, Jennifer Wilder, et al. Oral high dose vitamin B12 decreases renal superoxide and post-ischemia/reperfusion injury in mice [J].Redox Biology, 2020, 32: 101504.

50. Jeremiah Ogbadu, Gaaminepreet Singh, Kirti Gupta, et al. Ageing reduces angiotensin II type 1 receptor antagonism mediated pre-conditioning effects in ischemic kidneys by inducing oxidative and inflammatory stress [J].Experimental Gerontology, 2020, 135(1): 110892.

51. Rinaldo Bellomo, John A Kellum, Claudio Ronco. Acute kidney injury [J].BMJ Clinical Evidence, 2011, 380(9843): 756-766.

52. Klaus Höcherl, Christoph Schmidt, Michael Bucher. COX-2 inhibition attenuates endotoxin-induced downregulation of organic anion transporters in the rat renal cortex [J].Kidney international,2009,75(4):373-80.

53. Ding Chen-guang, Han Feng, Heli Xiang, et al. Role of prostaglandin E2 receptor 4 in the modulation of apoptosis and mitophagy during ischemia/reperfusion injury in the kidney [J].Mol Med Rep, 2019, 20(4): 3337-3346.

54. Christina Preising, Reinhard Schneider, Michael Bucher, et al. Regulation of expression of renal organic anion transporters OAT1 and OAT3 in a model of ischemia/reperfusion injury [J].Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2015, 37(1): 1-13.

55. Deng Cong, Chen Shan-shan, Li Xiong-feng, et al. Role of the PGE2 receptor in ischemia-reperfusion injury of the rat retina [J].Molecular Vision, 2020, 26: 36-47.

56. Zhu Li-yuan, Xu Chuan-sheng, Huo Xing-yu, et al. The cyclooxygenase-1/mPGES-1/endothelial prostaglandin EP4 receptor pathway constrains myocardial ischemia-reperfusion injury [J].Nature Communications, 2019, 10(1): 1888.

57. Cai Lin-lin, Xu Hai-tao, Wang Qi-long, et al. EP4 activation ameliorates liver ischemia/reperfusion injury via ERK1/2‑GSK3β‑dependent MPTP inhibition [J].International J Molecular Medicine, 2020, 45(6):1825-1837.

58. Christoph Sauvant, R Schneider, Hildegard Holzinger, et al. Indomethacin corrects alterations associated with ischemia/reperfusion in an in vitro proximal tubular model [J].American J Nephrology, 2010, 32(1): 57-65.

59. Hong Yu-Ah, Keum-Jin Yang, So-Young Jung, et al. Paricalcitol attenuates lipopolysaccharide-induced inflammation and apoptosis in proximal tubular cells through the prostaglandin E receptor EP4 [J].Kidney Research and Clinical Practice, 2017, 36(2): 145-158.

60. Yu Ah Hong, Keum-Jin Yang, So Young Jung, et al. Paricalcitol pretreatment attenuates renal ischemia-reperfusion injury via prostaglandin E receptor EP4 pathway [J].Oxidative Medicine and Cellular Longevity, 2017, 2017(3):1-17.

61. Robert W Schrier, Wang Wei. Acute renal failure and sepsis [J].New England J Medicine, 2004, 351(2): 159-169.

62. Makita N, Manaka K, Sato J, et al. V2 vasopressin receptor mutations [J]. Vitamins and Hormones, 2020, 113: 79-99.

63. Daniel G Bichet. Vasopressin receptor mutations in nephrogenic diabetes insipidus [J]. Semin Nephrol, 2008, 28(3): 245-51.

64. Nielsen S, Tae-Hwan Kwon, Jorgen Frøkiaer, et al. Regulation and dysregulation of aquaporins in water balance disorders [J].J Internal Medicine, 2007, 261(1): 53-64.

65. Tae-Hwan Kwon, Henrik Hager, Lene Nejsum, et al. Physiology and pathophysiology of renal aquaporins [J].Seminars in Nephrology, 2001, 21(3): 231-238.

66. Daniel G Bichet. Nephrogenic diabetes insipidus [J].Current Opinion in Pediatrics, 2017, 29(2): 199-205.

67. Li Jian-hua, Chou Chung-lin, Li Bo, et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus [J].The J Clinical Investigation, 2009, 119(10): 3115-3126.

68. Jeff M Sands, Harold E Layton. Advances in understanding the urine-concentrating mechanism [J].Annu Rev Physiol, 2014, 76: 387-409.

69. Tae-Hwan Kwon, Jørgen Frøkiær, Søren Nielsen. Regulation of aquaporin-2 in the kidney: A molecular mechanism of body-water homeostasis [J].Kidney Research and Clinical Practice, 2013, 32(3): 96-102.

70. Hanne B Moeller, Jeppe Praetorius, Michael R Rützler, et al. Phosphorylation of aquaporin-2 regulates its endocytosis and protein-protein interactions [J].Proceedings of the National Academy of Sciences of the United States of America, 2010, 107(1): 424-429.

71. Emma Tina Bisgaard Olesen, Michael Rutzler, Hanne B Moeller, et al. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus [J].Proc Natl Acad Sci USA, 2011, 108(31): 12949-12954.

72. Gao Min, Cao Rong, Du Sheng-nan, et al. Disruption of prostaglandin E2 receptor EP4 impairs urinary concentration via decreasing aquaporin 2 in renal collecting ducts [J].Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(27): 8397-8402.

73. Karthrin Eller, Tobias Weber, Monika Pruenster, et al. CCR7 deficiency exacerbates injury in acute nephritis due to aberrant localization of regulatory T cells [J].Journal of the American Society of Nephrology : JASN, 2010, 21(1): 42-52.

74. Dominik Wolf, Kathrin Hochegger, Anna M Wolf, et al. CD4+CD25+ regulatory T cells inhibit experimental anti-glomerular basement membrane glomerulonephritis in mice [J].J the American Society of Nephrology : JASN, 2005, 16(5): 1360-1370.

75. Chadban S J, Atkins R C. Glomerulonephritis [J].Lancet (London, England), 2005, 365(9473): 1797-1806.

76. Tadashi Nagamatsu, Hirohito Imai, Michiyo Yokoi, et al. Protective effect of prostaglandin EP4-receptor agonist on anti-glomerular basement membrane antibody-associated nephritis [J].J Pharmacological Sciences, 2006, 102(2): 182-188.

77. Riyaz Mohamed, Calpurnla Jayakumar, Ganesan Ramesh. Chronic administration of EP4-selective agonist exacerbates albuminuria and fibrosis of the kidney in streptozotocin-induced diabetic mice through IL-6 [J]. Laboratory Investigation: A J Technical Methods and Pathology, 2013, 93(8): 933-945.

78. Kazuhiro Furuhashi, Naotake Tsuboi, Asuka Shimizu, et al. Serum-starved adipose-derived stromal cells ameliorate crescentic GN by promoting immunoregulatory macrophages [J].J the American Society of Nephrology : JASN, 2013, 24(4): 587-603.

79. Ida Aringer, Katharina Artinger, Alexander H Kirsch, et al. Blockade of prostaglandin E receptor 4 ameliorates nephrotoxic serum nephritis [J].American J Physiology. Renal Physiology, 2018, 315(6): F1869-F1880.

80. Lin Yu-sheng, Mingli Hsieh, Yi-Ju Lee, et al. AH23848 accelerates inducible nitric oxide synthase degradation through attenuation of cAMP signaling in glomerular mesangial cells [J]. Nitric Oxide : Biology and Chemistry, 2008, 18(2): 93-104.

81. Jose M López-Novoa, Carlos Martínez-Salgado, Ana B Rodríguez-Peña, et al. Common pathophysiological mechanisms of chronic kidney disease: therapeutic perspectives [J]. Pharmacology & Therapeutics, 2010, 128(1): 61-81.

82. Duan Jia-yu, Duan Guang-Cai, Wang Chong-Jian, et al. Prevalence and risk factors of chronic kidney disease and diabetic kidney disease in a central Chinese urban population: a cross-sectional survey [J].BMC Nephrology, 2020, 21(1): 115.

83. Hiddo Lambers Heerspink, Dick de Zeeuw. Novel drugs and intervention strategies for the treatment of chronic kidney disease [J]. British J Clinical Pharmacology, 2013, 76(4): 536-550.

84. Karina Thieme, Syamantak Majumder, Angela S Brijmohan, et al. EP4 inhibition attenuates the development of diabetic and non-diabetic experimental kidney disease [J].Scientific Reports, 2017, 7(1): 3442.

85. Francisco J Lopez-Hernandez, Jose M Lopez-Novoa. Role of TGF-beta in chronic kidney disease: an integration of tubular, glomerular and vascular effects [J]. Cell Tissue Res, 2012, 347(1): 141-154.

86. Yang Guang-Xia, Xu Yu-yin, Fan Ya-Ping, et al. A maladaptive role for EP4 receptors in mouse mesangial cells [J].PLoS One, 2014, 9(8): e104091.

87. Kazuhiko Mizukami, Hiroyuki Yoshida, Eisuke Nozawa, et al. Renoprotective effects of the novel prostaglandin EP4 receptor-selective antagonist ASP7657 in 5/6 nephrectomized chronic kidney disease rats [J].Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392(4): 451-459.

88. Hu Chun, Sun Lin, Xiao Ya-chun, et al. Insights into the mechanisms involved in the expression and regulation of extracellular matrix proteins in diabetic nephropathy [J].Current Medicinal Chemistry, 2015, 22(24): 2858-2870.

89. Peng Fang-Fang, Xiao Ze-Ling, Chen Hong-Min, et al. Parathyroid hormone inhibits TGF-β/Smad signaling and extracellular matrix proteins upregulation in rat mesangial cells [J].Biochemical and Biophysical Research Communications, 2016, 478(3): 1093-1098.

90. Convento M S, E Pessoa, M A Dalboni, et al. Pro-inflammatory and oxidative effects of noncrystalline uric acid in human mesangial cells: contribution to hyperuricemic glomerular damage [J].Urological Research, 2011, 39(1): 21-27.

91. Tadashi Nagamatsu, Toshiyuki Nagao, Jun-ichi Koseki, et al. Involvement of prostaglandin E2 in clearance of aggregated protein via protein kinase A in glomeruli [J]. Japanese J Pharmacology, 2001, 85(2): 139-145.

92. Cao Ying-Jie, Pan Tian-Yi, Chen Xiao-xian, et al. EP4 knockdown alleviates glomerulosclerosis through Smad and MAPK pathways in mesangial cells [J].Molecular Medicine Reports, 2018, 18(6): 5141-5150.

93. Erin M Stitt-Cavanagh, Wissam H Faour, Kaede Takami, et al. A maladaptive role for EP4 receptors in podocytes [J]. J the American Society of Nephrology: JASN, 2010, 21(10): 1678-1690.

94. Peter Harris, Sandro Rossetti. Molecular diagnostics for autosomal dominant polycystic kidney disease [J].Nature Reviews. Nephrology, 2010, 6(4): 197-206.

95. Hannah C Chapin, Michael Joseph Caplan. The cell biology of polycystic kidney disease [J].J Cell Biol, 2010, 191(4): 701-710.

96. Thomas Natoli, Tiffany C Gareski, William R Dackowski, et al. Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures [J].Am J Physiol Renal Physiol, 2008, 294(1): F73-83.

97. Gerard Elberg, Dorit Elberg, Teresa V Lewis, et al. EP2 receptor mediates PGE2-induced cystogenesis of human renal epithelial cells [J].American J Physiology. Renal Physiology, 2007, 293(5): F1622-F1632.

98. Malcolm R Ogborn, Evan Nitschmann, Nitschmann Bankovic-Calic, et al. Dietary conjugated linoleic acid reduces PGE2 release and interstitial injury in rat polycystic kidney disease [J].Kidney International, 2003, 64(4): 1214-1221.

99. Franck A Belibi, Gail Reif, Darren P Wallace, et al. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells [J].Kidney International, 2004, 66(3): 964-973.

100. Anll Karihaloo, Christian Nickel, Lloyd G Cantley. Signals which build a tubule [J]. Nephron Experimental Nephrology, 2005, 100(1): e40-e45.

Metrics

Viewed

Full text

Abstract

Abstract
References
Related Articles
Recommended Articles
Metrics

TOP

[1]	LIU Chang, MENG Xian-yong, DONG Xiao-hua. Research Progress on Pathogenesis and Therapeutic Drugs of Alzheimer’s Disease [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 36-40.
[2]	HAI Ji-tao, LUO Huan-min. Progress on the Relationship between Pathogenic Microorganisms and Alzheimer’s Disease [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 58-64.
[3]	ZHANG Hao-ting, SONG Gui-qin, CUI Ruo-tong, HAO Min, WANG Wen-dong. Mining Target Genes of Alzheimer’s Disease Associated with Biological Clock by Bioinformatics Analysis [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 1-7.
[4]	DU Bao-ze, TAN Xiao-hong. Preparation and Pharmacological Activities of Resveratrol Nanoparticles [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 8-16.
[5]	XU Jia-qi, ZHANG Hai-hong. Research Progress on Physiological Activity of Patchouli [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 27-32.
[6]	SUN Yi, HOU Xue-qin, WANG Fu-gang. Research Progress of Danggui Shaoyao Powder in Improving Cognitive Function [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 42-46.
[7]	WANG Di，CHENG Xiu-mei，REN Wei-wei, et al. Research Progress of Endothelin in the Pathogenesis of Gynecological Diseases [J]. Acta Neuropharmacologica, 2019, 9(6): 31-35.
[8]	SONG Yi-lei，HOU Xue-qin，HAO Ji-fu. Advances in Research on Modern Pharmacological Effects and Clinical Application of Cnidium [J]. Acta Neuropharmacologica, 2019, 9(6): 58-63.
[9]	SUN Cheng-cheng，LIU Jian-gang，LIU Mei-xia，LI Hao，LUO Zeng-gang. Exploration of Pathological Mechanism of Vascular Dementia Induced by Chronic Cerebral Hypoperfusion and Production of Several Common Animal Models [J]. Acta Neuropharmacologica, 2019, 9(1): 13-17.
[10]	ZHU Chao，DU Ning-ning，ZHOU Yan-meng，WANG Hao，HOU Xue-qin，ZHANG Fang-fang，TAN Rui，GAO. Increased Blood Pressure Variability Impairs Memory in Rats [J]. Acta Neuropharmacologica, 2018, 8(5): 79-80.
[11]	Gill SE1,5#，Halene T1,6#，Rajarajan P2，Chandrasekaran S2，Kassim B1，Fullard JF1,5，Loh YHE8，Bannon MJ7，. 3D Genome Mapping in Dopaminergic Neurons from Adult Human Midbrain [J]. Acta Neuropharmacologica, 2018, 8(4): 31-32.
[12]	YUAN Yong-gui. A Study of Diagnosis and Early Efficacy Prediction Biomarkers for Major Depressive Disorder [J]. Acta Neuropharmacologica, 2018, 8(4): 42-44.
[13]	YANG Wen-zhong1, ZHOU Xue-yan1, MA Tao1,2,3. Impaired mRNA Translational Capacity is Correlated with Aging-Dependent Memory Deficits and Behavioral Inflexibility* [J]. Acta Neuropharmacologica, 2018, 8(4): 50-52.
[14]	DU Guan-hua，ZHANG Wen，DU Li-da，MA Yin-zhong，LI Li，WANG Yue-hua. New Strategies for the Drug Development of Anti-cerebral Ischemia —Advances in the Etiology and Drug Development of Acute Cerebral Ischemia [J]. Acta Neuropharmacologica, 2018, 8(1): 1-8.
[15]	LIN Zhi-bin. Pharmacological Progress of Ganoderma on Anti-aging and Anti-Alzheimer’s Disease [J]. Acta Neuropharmacologica, 2018, 8(1): 9-15.